Cardioprotective and Lipid Lowering Effects Tabebuia Impetiginosa ( Lapacho Tea) on Male Rats Fed A High Fat and Fructose Diet
Beatrice
N. Kiage-Mokua1,2*, Michael de Vrese3, Jürgen
Schrezenmeir4,5
1Max
Rubner-Institute, Federal Research Institute of Nutrition and Food, Department
of Microbiology and Biotechnology, Kiel, Germany
2Jomo
Kenyatta University of Agriculture & Technology, Department of Food Science
and Technology, Nairobi, Kenya
3Max
Rubner-Institute, Federal Research Institute of Nutrition and Food, Department
of Microbiology and Biotechnology, Kiel, Germany
4Max
Rubner-Institute, Federal Research Institute of Nutrition and Food, Department
of Physiology and Biochemistry of Nutrition, Karlsruhe, Germany
5Clinical
Research Center, Kiel Innovation and Technology Center, Kiel, Germany
*Corresponding author: Beatrice N. Kiage-Mokua, Jomo
Kenyatta University of Agriculture and Technology, P.O BOX 62000-00200,
Nairobi, Kenya. Tel: +254711641359; Email: beatrice.kiage@jkuat.ac.ke
Received
Date: 20
September, 2018; Accepted Date: 02 October,
2018; Published Date: 08 October,
2018
Citation: Kiage-Mokua BN, de Vrese M, Schrezenmeir J (2018) Cardioprotective and Lipid Lowering Effects Tabebuia Impetiginosa ( Lapacho Tea) on Male Rats Fed A High Fat and Fructose Diet. J Obes Nutr Disord: JOND-131. DOI: 10.29011/2577-2244. 100031
1. Abstract
Obesity is a major health issue in the developed countries with a similar trend in the developing countries too. High energy diets, notably from fats and sugars (high-fat/high-sugar diet: HF/HSD) is linked to the development of obesity which causes insulin resistance a hallmark of type 2 diabetes and an important factor in cardiovascular disease. In earlier studies Tabebuia impetiginosa extract inhibited lipase and slowed the increase of postprandial triglycerides in rats given a fat load. Therefore, we investigated its triglyceride lowering and cardio protective effects in Wistar rats fed a High Fat and Fructose Diet (HFFD). In a dose-effect trial three groups of 21 rats each were fed for 74 days only HFFD (controls), or HFFD, to which either 0.3 (HFFD+lowL) or 0.6 mg dry Tabebuia impetiginosa extract per kg food (HFFD+highL) was added. Fasting blood samples were drawn before and at the end of intervention. Tabebuia impetiginosa extract lowered dose-dependently and significantly (p<0.05) plasma Triglycerides (TG), Total Cholesterol (TC), Atherogenic Index (AI), Cardiovascular Risk Index (CRI) and liver TG, as well as Fasting Blood Glucose (FBG) and Glycated hemoglobin (HbA1c), with correlation coefficients (R) between±0.288 and ±0.519 (General Linear Model (GLM) procedure). Fat malassimilation was not observed. In conclusion, Tabebuia impetiginosa extract might be a promising adjunct in the management of hypertriglyceridemia and other risk factors of cardiovascular disease, common in obesity and diabetes.
2. Keywords: Cardiovascular Disease; Diabetic Obese Rats; High Fat and Fructose Diet; Lipase Inhibitor; Triglycerides; Tabebuia impetiginosa Extract (Lapacho Tea)
3.
Introduction
3.1. Background
Obesity is a major health issue in
the developed countries with a similar trend being now in the developing
countries too. The consumption of high energy diets, notably from fats and
sugars (High-Fat/High-Sugar Diet: HF/HSD) is linked to the development of
obesity because it causes overconsumption of calories [1].
In fact, obesity is associated with insulin resistance which is the hallmark of
type 2 diabetes and a major risk factor in cardiovascular disease. The
prevalence of obesity and type 2 diabetes has escalated globally in the recent
past due to a combination of caloric overconsumption and physical inactivity.
An increased use of sugar in the form of high fructose corn syrup and fat in
modern diets is associated with the rise of the obesity and diabetic epidemics [2,3]. Fructose has unique metabolic properties, triggering
de novo lipogenesis and
causing overproduction of fatty acids which are deposited in organs. This may
culminate in insulin deficiency and increase cardiovascular disease risk [4]. Combining fructose with a high fat diet in rodents
causes insulin resistance, leptin resistance, type 2 diabetes and dyslipidemia
which resemble the human metabolic syndrome [5].
Dyslipidemia including elevated triglycerides as part
of the metabolic syndrome is considered an independent risk factor for
cardiovascular diseases and atherosclerosis [6,7].
In order to prevent cardiovascular diseases, one needs to address dyslipidemia,
and in particular elevated plasma triglycerides and cholesterol [7]. Lifestyle changes through diet and exercise can
lower triglycerides and all other features of the metabolic syndrome and
therefore, currently remain the cornerstones of treatment [7]. However, many patients require drugs since they
may fail to meet the required targets and due to progressing development of
disease. Drugs such as fibrates, niacin/nicotinic acid and statins are used for
treating elevated triglycerides [8]. In some
instances, there may be need to use a combination of these drugs [9], which may trigger serious side-effects like myopathy
and rhabdomyolysis, especially when statins and fibrates are combined [10]. Moreover, Kolovou and colleagues [7] note that these drugs may fail to address
hypertriglyceridemia sufficiently and hence alternative approaches are needed.
Plants have been man’s
companion for a long time and are a basis for the
development of many conventional drugs [11]. The WHO encourages the use of
plants in form of herbal medicine in the treatment of various illnesses,
acknowledging that up to 80% of the population in the developing countries use
traditional medicine in primary healthcare [11,12]. However, it emphasizes the need
for studies to authenticate the use and safety of herbal medicine in the
population through rigorous scientific scrutiny [13].
Tabebuia
impetiginosa
(Lapacho tea tree) is a tree from the Bignoniaceae family, native to South America from Brazil
to northern Argentina and the extract of the inner back was traditionally used
to treat diabetes, ulcers, cancer, malaria, stomach and bladder disorders [14]. Lapachol and β-lapachone
are components of methanolic extracts of Tabebuia impetiginosa which
show bioactivity against various ailments [14]. In vitro
studies indicated that an ethanolic extract of Lapacho tea inhibits pancreatic
lipase [15]. Accordingly, in an acute experiment with Wistar rats
treated with Triton-WR-1339 and fed on a high lipid load, ethanolic extracts of
Tabebuia
impetiginosa reduced the rate of increase of post-prandial
triglycerides in the plasma of the rats probably by inhibiting pancreatic lipase
[16].
Trials with Orlistat demonstrated that long-term
lipase inhibition may reduce fasting and postprandial triglyceridemia, fasting
LDL cholesterol (LDL-C) and diabetes incidence [17,18]. To date, no study has been done on the effect of
Lapacho tea extract on plasma lipids, glycemia and insulin resistance in a
long-term dose effect experiment.
3.2. Objectives
Thus, the primary objective of the
study was to examine triglyceride lowering and cardioprotective effects of
Lapacho tea extract in rats with diabetes and obesity, which were induced by
feeding a fat- and fructose-rich diet. This model was chosen in order to
investigate the effects of overconsumption of fat and fructose in the human
diet since it mimicks the dietary habits in humans.
4.
Materials and Methods
All
aspects of animal care and experimentation performed in this study conformed to
the Guide for Care and Use of Laboratory Animals of the National Institutes of
Health (NIH) and were in accordance with the European Economic
Community (EEC) directive of 1986 (86/609/EEC) and were approved by the
ethical committee of the Ministry for Agriculture, the Environment and Rural
Areas of Schleswig-Holstein, Germany.
4.1. Study Design
63
six weeks old Wistar rats, weighing 196 ± 11 g,
were randomly divided into three even-numbered groups: a control group (HFFD
only) and two experimental groups receiving HFFD plus either 0.3 mg (HFFD+lowL)
or 0.6 mg/kg Lapacho tea dry plant extract (HFFD+highL). Diets were fed for 74
days to the individually housed rats, experimental unit was the single animal.
4.2. Experimental Animals, Housing and Interventions
Three-week-old
male Wistar rats (Wistar Han IGS; strain code: 273 Charles Rivers, 97633
Sulzfeld, Germany), weighing 50 g at the time of arrival, were individually
housed in metal cages at ambient temperature and humidity with a 12 h
light-dark cycle (lights on at 07:00). Cages were lined with carton material
and sawdust for bedding material, which was changed weekly. Water and food were
available ad
libitum and were changed daily, uneaten food was weighed again early
in the morning. Until the trials started, animals were maintained for two weeks
on Ssniff® NR pellets (Ssniff®, Germany, containing 17.5, 34.8 and 47.7% of
energy fat, protein and carbohydrates), and in the third week on the HFFD diet (Table 1).
Blood was collected via retro bulbar bleeding into EDTA
tubes before intervention, in order to measure baseline parameters (day 0), and
at the end of the intervention (day 74) via the abdominal aorta. Urine and
faeces were collected before and at the end of the intervention, during 4-day
balance periods, in metabolic cages. Body weight was measured weekly, while
food consumption was recorded thrice weekly. At the end of the intervention
period, rats were sacrificed after a 12h fast between 7.30 and 11.30h. Before
termination, the rats were anaesthetized by intraperitoneal ketamine-xylazine
anaesthesia (mixed in the ratio 4:1) with 0.25 mL/100 g body weight, and then
terminated by cardiac puncture injection. Blood was collected, plasma
immediately separated by centrifugation (4000 ´ g for 10 min), and stored at -20°C, while organ aliquots (liver, visceral,
subcutaneous and muscle tissues) were excised immediately using dissection
method from the carcass, weighed and snap-frozen in liquid nitrogen and stored
at -80°C until further analysis. The
technical staff involved in sample analysis and the scientist responsible for
the statistical data analysis were not involved in the animal handling and
sample collection during experiments and had no access to the animal facility.
4.3. Experimental
Outcomes
According to our hypothesis that
the expected health effects of Lapacho tea are based primarily on its lipase
inhibitory activity, plasma triglycerides concentration was chosen as the
primary parameter of the study. Secondary parameters were the
effects of Lapacho tea on Total Cholesterol (TC), HDL-Cholesterol (HDL-C) and LDL-C, on liver metabolism
(liver fat, liver Triglycerides (TG), C-Reactive Protein (CRP), Gamma-Glutamyl
Transferase (GGT), Alanine Aminotransferase (ALT)) and glycemia (Fasting Blood
Glucose (FBG), glycated haemoglobin (HbA1c)).
4.4. Sample
Size and Randomisation
The number of required animals was
estimated on the basis of earlier trials and verified by a pilot trial (not
published). Thus, the difference between the intervention-induced changes of
the primary parameter (plasma TG) in the control and experimental group was
used for calculation of sample size in the main experiment: From an expected
mean difference of 34.5 mg/dL, standard deviations of 57.9 or 19.7 mg/dL, α = 0.05, and β = 0.10,
and applying one-sided statistical tests (because Lapacho tea as a lipase
inhibitor [15] will decrease plasma TG - if
there is any effect at all), this required at least 17 rats per group. Group
size was increased to 21 rats, so that altogether 63 six-week-old rats were distributed randomly to the
control and experimental groups using computer-generated random numbers.
4.5. Statistical
Analysis
Since some of the parameters
required killing of the animals, the primary evaluation focused on values
measured at the end of the experiment, in order to treat all data in the same
manner.
For statistical analysis of a dose
effect of Tabebuia
impetiginosa extract on HFFD fed rats the General Linear Models
(GLM) procedure was applied using the software package "Statgraphics Plus
for Windows" (version 4.5, Manugistics, Rockville, MD, USA). This
corresponded largely with a simple linear regression model based on 3 Lapacho
tea concentrations (0.0, 0.3 and 0.6 mg dry extract/kg diet) as the X and the
values for each tested parameter of all rats as the Y values. This provided
correlation coefficients (values between -0.5 and +0.5 mean a weak
correlation), coefficients of variation (CV, the proportion of the variance (or
the dose-effect) predictable from the independent variable) and the p-values of
the Lapacho tea effects on the parameters considered at the 95% confidence
level (as determined by ANOVA).
4.6. Diets
The
Tabebuia
impetigenosa bark, which is marketed as Lapacho tea, was purchased
from Libertee, Kiel, Germany. Dried and ground material was mixed with a
fivefold volume of ethanol (abs., v/v) and extracted for 2 h at 37°C. The mixture was then centrifuged at 6100 ´
g for 10 min. The resulting extract contained 0.13 mg dry plant residue/mL. All experimental and control
diets were based on Ssniff® NR
powder, a complete (breeding and maintenance) feed for nude rats with enhanced
energy density (GE = 17.4 MJ/kg; Ssniff GmbH, 59494 Soest, Germany) as shown in
table 1.
From
this the fat-
and fructose-enriched control diet (HFFD) was prepared by adding 40 g of lard
and 20 g of fructose to 100 g Ssniff®-NR
powder. The
total energy was provided by 56% fat, 14% protein and 30% carbohydrates (Table 1). Both experimental diets (HFFD+lowL and
HFFD+highL) were prepared by carefully mixing 0.3 or 0.6 mg dry Lapacho tea
plant extract with one kg of HFFD powder each (Table 1).
4.7. Determination of Biochemical Parameters
Plasma TG,
TC, LDL-C, HDL-C, FBG, urinary glucose (UG), ALT and HbA1c
were analysed enzymatically using commercially available kits (Thermo Fisher
Scientific, Passau, Germany) as described by the manufacturers in a Konelab 20i
clinical chemistry analyser (Kone, Helsinki, Finland) in both experiments.
Fasting insulin was determined by radio immuno assays (Rat Insulin RIA kit,
Linco Research Inc., St. Charles, Missouri, USA) and insulin resistance was
determined by homeostasis model assessment (HOMA-IR) which is a mathematical
term based on glucose and insulin interaction in different organs, including
the pancreas, liver and peripheral tissues [19].
HOMA-IR
was calculated as HOMA-IR =
[fasting insulin (mU/L) × fasting glucose
(mmol/L)]/405, the Atherogenic Index (AI) was calculated as AI = [LDL-C (mg/dL)] / [HDL-C (mg/dL)] and
the Coronary Risk Indices (CRI) were calculated as TC / HDL-C and TG / HDL-C
(expressed as mg/dL) [20].
4.8.
Extraction of Lipids from Faeces
In
both experiments, lipids were extracted from faeces according to Dole [21]. Briefly, hydrochloric acid (4 mol/L, 2.5 mL) was
added to 500 mg of dried and powdered faeces, mixed well and heated at 100°C for 15 minutes then cooled on ice for 5
minutes. 7.5 mL of a 40:10:1, isopropanol, heptane and sulphuric acid solution
was then added to the mixture, mixed well and incubated for 1 hour at room
temperature. Heptane (5 mL) and distilled water (7.5 mL) were then added
causing the mixture to separate into two phases with the heptane phase,
containing the lipids, on the top. The heptane phase (2.5 mL) was recovered by
siphoning, evaporated to dryness and then used for lipid quantification. Total
lipids content was quantified by subtracting the empty weight of the glass from
the weight of the glass plus dry lipid extract.
4.9. Extraction of Lipids from the Liver
In
the experiments, liver triglycerides were extracted according to the method by
Folch [22]. Briefly, this is a biphasic solvent system
procedure for lipid extraction, whereby 1 g of liver was homogenised with a
20-fold its volume with chloroform /methanol (2:1(v/v)) using a Potter-Elvehjem
glass homogeniser. The homogenate was then mixed with 0.2 times its volume with
an aqueous 0.58% NaCl-solution, and centrifuged, thus obtaining a biphasic
system containing lipids in the lower phase. This lower phase was siphoned,
evaporated to dryness by nitrogen gas then reconstituted using isopropanol with
10% Triton X-100, and the levels of triglycerides assayed enzymatically using
commercially available kits (Thermo Fisher Scientific, Passau, Germany) as
described by the manufacturers in a spectrophotometer (Uvikon 860, Kontron,
Burladingen, Germany) at 510 nm.
5.
Results and Discussion
High fat and sugar diets induce gut microbiota dysbiosis, causes gut
inflammation, triggers remodelling of gut-brain axis leading to an increase in
body fat mass [1,23].
From our study, we postulate that lapacho tea, which is a lipase inhibitor [16], may have favourably improved the gut
microbiome by reversing dysbiosis hence the hypolipidemic and cardioprotective
effects observed in the rats fed a high fat and fructose diet.
Morphological
and metabolic data at the start of the experiment and the effects of 0.3 and 0.6 mg dry Lapacho-tea extract /
kg food on various body and metabolic parameters compared with controls are
shown in table 2. The average energy intake,
body weight, liver weight and percentage of liver fat content were similar in
the Lapacho groups and the control rats, and liver enzymes (ALT, GGT) were not
affected significantly, whereas liver TG were decreased with increasing
administration of Lapacho tea extract (p = 0.054).
The metabolic parameters were
favourably affected by Lapacho tea. With increasing doses of Lapacho tea
extract, plasma TG and TG/HDL-C, TC and TC/HDL-C, FBG and HbA1c significantly
decreased (p<0.05). The CRP increased significantly (p<0.05). LDL-C also decreased,
and HDL-C increased, however, not significantly. For
the “Significant” parameters, between 8 and 27% of the positive effect
could be explained by the administration of Lapacho tea extract (corresponding
to a CV = 8.3 to 27.0%), with the corresponding correlation coefficients
ranging between ±0.288 and ±0.519. This implies that Tabebuia
impetiginosa extract may possess hypotriglyceridemic and
cardioprotective effects, since atherogenic and coronary risk indices are
powerful predictors for cardiovascular disease risk [24,25],
and elevated plasma lipids and blood glucose are common scenarios in diabetes
and the metabolic syndrome.
In fact, Tabebuia impetiginosa extract
inhibited pancreatic lipase in vitro [15] and delayed the rate of increase
of postprandial TG in Triton WR-1339 treated rats fed a fat load, during an
acute experiment [16]. In our study long-term
administration of Tabebuia impetiginosa extract improved diabetes in the rats as
indicated by a less pronounced increase in Urinary Glucose (UG), and a
significant reduction of FBG and %HbA1c in comparison to the control,
indicating improved glycemic control. Indeed, these effects are not surprising,
since Tabebuia
impetiginosa extract delayed increase in postprandial TG [16] and postprandial hypertriglyceridemia as well as
intrahepatic lipogenesis resulting in hypertriglyceridemia, are associated with
gluconeogenesis and insulin resistance [16,26].
Hepatic de
novo biosynthesis and VLDL release may result in
hypertriglyceridemia, if VLDL clearance by lipoprotein lipase does not increase
correspondingly [27]. Loss of insulin activity results in
lower expression of lipoprotein lipase and consequently in reduced clearance of
TG in VLDL and chylomicrons. This may explain why Orlistat, a potent lipase
inhibitor, has effects on glycemia, too [17]. The findings of our studies are also in
agreement with reported folkloric use of Tabebuia impetiginosa in the diabetes treatment [14].
Blocking of digestive enzymes is among the current trends in obesity
and diabetes treatment. This, however, may result in unfavourable side-effects
such as steatorrhea in Orlistat treatment [28,29]. In contrast, Tabebuia impetiginosa extract did
not increase fecal fat excretion (Table 2) even
though it a) inhibits pancreatic lipase, as indicated by in vitro data [15] and b) delays the increase of
postprandial TG after a fatty meal in a rodent model [16]. This may be due to: a) incomplete
inhibition of the lipase as a result of a low dosage of the active component in
our study and b) reversible inhibition of lipase due to a lower affinity of the
active component to lipase as compared to Orlistat. Dissociation during transit
through the small bowel and absorption or degradation of the active component
and hence, loss of activity during gastrointestinal transit may withdraw the
active component from the inhibitory reaction. The lack of steatorrhea when
using Lapacho tea extract may be an advantage over Orlistat, which has never
been a fully successful anti-obesity drug due to gastrointestinal side effects
such as steatorrhea [30].
Whether this holds true has to be clarified by dose-effect studies in humans
evaluating effects and side-effects.
In Orlistat, lipase inhibition causes a decrease in body weight [28]. However, we did not find a decrease in
body weight by Lapacho tea extract (Table 2).
This could be due to the lack of energy losses by steatorrhea or by more
complex regulatory effects bound to the transit of fat into lower parts of the
intestine. Liver steatosis is a common cause of liver injury in obesity and
diabetes [31]. Although the liver weights and liver TG
concentrations were slightly higher in Tabebuia impetiginosa extract group (Table 2), these did not seem to cause liver injury,
since ALT, CRP and GGT levels did not significantly differ from the control. In
fact, liver TG were significantly reduced in the high Lapacho tea diet (Table 2). We may therefore speculate that Tabebuia
impetiginosa extract protected the rats against liver steatosis.
6.
Conclusions
We
report for the first time that long-term administration of Tabebuia impetiginosa extract to
rats fed a high fat high fructose diet, significantly and dose-dependently
lowered plasma TG, TC, AI, CRI and liver triglycerides as well as fasting blood
glucose and HbA1c. Similar beneficial effects are known for other lipase
inhibitors in humans. This, together with the general acceptance of
the fat- and fructose-rich fed rat as a model mimicking dietary habits in
humans in industrialized countries and the comparability of the underlying
metabolic mechanisms in rats and humans, suggests that our results can
qualitatively be transferred to humans. Thus, Lapacho tea extract may be useful
for treating and
preventing, respectively, hypertriglyceridemia and cardiovascular disease which
are common traits of the metabolic syndrome, especially in Western societies
with its high consumption of fat and sugars. The observed lack of steatorrhea,
which might, at least partly, result from a lower lipase inhibition by Lapacho
tee extract, raises hopes for fewer side effects compared to Orlistat. This,
however, has to be verified in human trials.
7.
Acknowledgements
We are grateful to Frauke Repenning
and Kirsten Gonda for technical assistance and Jochen Kunze, Karina Horn and Dieter
Siewertsen for animal care.
8.
Conflicts of Interest
The
authors declare no competing interests, however, J. Schrezenmeir held a patent
on lipase inhibitory extracts including that from Lapacho tea (US 2008/0299234
A1, (Schrezenmeir, 2006 )).
9. Funding Sources
Dr.
Beatrice N. Kiage-Mokua had received a scholarship from DAAD, Germany.
|
Ssniff NR1 Control diet Experimental diets |
|||
Nutrient |
|
HFFD2,3 |
HFFD+lowL2,3 |
HFFD+highL2,3 |
Crude protein |
41% |
14% |
14% |
14% |
Crude fat |
14% |
56% |
56% |
56% |
Carbohydrates |
45% |
30% |
30% |
30% |
Lapacho tea extract |
|
|
0.3 mg |
0.6 |
1percentage of gross energy (GE = 17.4 MJ / kg ssniff NR powder). |
||||
2percentage of total energy of the diet. |
||||
3mg dry plant residue/kg diet. |
Table 1: Composition of the diets.
HFFD |
HFFD+lowL |
HFFD+highL |
|
|
|
||||
Parameters |
Baseline |
End of experiment |
Baseline |
End of experiment |
Baseline |
End of experiment |
p |
R2(%) |
Corr. Coeff. |
Body weight (g) |
122 ± 11.5 |
412 ± 33.5 |
122 ± 14.7 |
421 ± 44.0 |
123 ± 8.74 |
418 ± 27.4 |
0.563 |
0.6 |
0.074 |
Energy intake (KJ/day) |
182 ± 13.5 |
207 ± 24.3 |
179 ± 17.5 |
215 ± 24.8 |
180 ± 15.3 |
203 ± 17.5 |
0.503 |
0.7 |
0.085 |
Liver weight (g) |
9.87 ± 1.23 |
10.3 ± 1,26 |
10.0 ± 0.78 |
0.685 |
0.3 |
0.052 |
|||
Liver fat (%) |
|
2.08 ± 1.53 |
|
2.38 ± 0.83 |
|
2.39 ± 0.68 |
0.389 |
1.2 |
0.110 |
Liver TG(mg/g) |
364 ± 390 |
384 ± 252 |
194 ±125 |
0.054§ |
6.0 |
-0.244 |
|||
GGT (U/L) |
4.21 ± 3.81 |
6.67 ± 5.12 |
2.24 ± 1.52 |
9.38 ± 18.94 |
3.46 ± 2.82 |
6.59 ± 7.21 |
0.955 |
0.0 |
-0.007 |
ALT (U/L) |
30.8 ± 7.26 |
45.1 ± 31.3$ |
28.3 ± 6.20 |
66.3 ± 89.7$ |
26.0 ± 5.50 |
79.1 ± 149$ |
0.352 |
1.6 |
0.126 |
CRP (U/L) |
5.07 ± 0.63 |
3.51 ± 1.89 |
4.96 ± 0.33 |
4.43 ± 0.49 |
4.83 ± 0.49 |
4.42 ± 0.51 |
0.015* |
9.3 |
0.304 |
TG (mg/dl) |
42.5 ± 12.1 |
69.6 ± 18.6 |
53.4 ± 21.3 |
60.9 ± 15.5 |
50.9 ± 13.8 |
58.4 ± 11.5 |
0.022* |
8.3 |
-0.288 |
TG/HDL |
0.81 ± 0.27 |
1.70 ± 0.60 |
1.00 ± 0.31 |
1.44 ± 0.40 |
0.97 ± 0.27 |
1.33 ± 0.34 |
0.014* |
9.5 |
-0.308 |
TC (mg/dL) |
75.9 ± 11.9 |
63.6 ± 10.5 |
74.0 ± 12.2 |
57.7 ± 8.66 |
73.8 ± 11.2 |
55.8 ± 5.86 |
0.004* |
12.6 |
-0.355 |
HDL-C (mg/dL) |
53.7 ± 8.47 |
42.6 ± 7. 39 |
53.1 ± 7.56 |
42.8 ± 6.00 |
53.6 ± 9.26 |
44.4 ± 4.81 |
0.337 |
1.5 |
0.123 |
LDL-C (mg/dL) |
12.8 ± 4.91 |
6.97 ± 3.35 |
12.7 ± 3.92 |
6.62 ± 3.28 |
12.5 ± 3.02 |
5.69 ± 1.99 |
0.166 |
3.1 |
-0.177 |
TC/HDL-C |
1.42 ± 0.15 |
1.51 ± 0.27 |
1.39 ± 0.11 |
1.35 ± 0.12 |
1.39 ± 0.10 |
1.26 ± 0.07 |
0.000* |
27.0 |
-0.519 |
LDL-C/HDL-C |
0.24 ± 0.10 |
0.16 ± 0.07 |
0.24 ± 0.06 |
0.15 ± 0.07 |
0.24 ± 0.06 |
0.13 ± 0.04 |
0.519 |
0.7 |
0.083 |
FBG (mg/dL) |
146 ± 30.7 |
251 ± 56.4 |
128 ± 27.3 |
220 ± 35.3 |
132 ± 23.9 |
215 ± 32.0 |
0.009* |
10.7 |
-0.327 |
HbA1C (%) |
3.37 ± 0.14 |
3.94 ± 0.18 |
3.03 ± 0.16 |
3.93 ± 0.23 |
3.28 ± 0.19 |
3.80 ± 0.15 |
0.018* |
8.9 |
-0.298 |
121 male Wistar rats per group were given either a High Fat and Fructose Diet (HFFD) only or this diet plus either 0.3 mg/ g (HFFD+lowL) or 0.6 mg/g (HFFD+highL) of Lapacho tea extract for 74 days and various parameters evaluated at the start and end (or only end) of the experiment. Values are expressed as mean ± SD. *p < 0.05, §p < 0.1 (GLM). $ n = 15 |
Table 2: Effects of different doses of Lapacho tea ethanolic extract on male Wistar rats fed on a HFFD diet in the main (dose-effect) experiment1.